Article Text

Download PDFPDF
Role of Lymphadenectomy for Uterine Sarcoma: A Meta-Analysis
  1. Manfei Si, MD,
  2. Lin Jia, PhD,
  3. Kun Song, PhD,
  4. Qing Zhang, PhD and
  5. Beihua Kong, PhD
  1. Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji’nan, Shandong, P. R. China.
  1. Address correspondence and reprint requests to Beihua Kong, MD, PhD, Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 107W, Wenhua Road, Ji’nan, Shandong 250012, P. R. China. E-mail: kongbeihua{at}sdu.edu.cn.

Abstract

Objective Uterine sarcomas are rare, highly aggressive tumors with an unfavorable prognosis. The role of lymphadenectomy (LAD) remains controversial for this particular tumor type. To examine whether LAD can assist in prognosis or clinical benefits for uterine sarcoma patients, we performed a meta-analysis based on published studies.

Methods We initially identified published studies by searching the PubMed database up to 30 November 2015. Study quality was evaluated systematically using the Newcastle-Ottawa Scale for assessing the quality of studies for inclusion in meta-analyses. Pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated using Stata software version 12.0.

Results Our search retrieved 14 eligible studies, involving a total of 4867 patients, including 1356 (27.9%) patients who had LAD. The pooled RR for uterine leiomyosarcoma (uLMS) in patients with LAD in 5 trials was 0.90 (95% CI, 0.62–1.31) and for endometrial stromal sarcoma (ESS) in 11 trials was 0.96 (95% CI, 0.69–1.34), suggesting that there was no significant benefit of LAD in improving overall survival (P < 0.05). A random-effects model was chosen to estimate the RRs in view of the significant heterogeneity in the included studies (uLMS: Cochran Q test: P = 0.022, I2 = 64.9%; ESS: Cochran Q test: P = 0.005, I2 = 60.1%). No publication bias was detected by the Egger and Begg tests (uLMS: Begg: P = 0.221, Egger: P = 0.148; ESS: Begg: P = 1.000, Egger: P = 0.928).

Conclusions Based on currently available evidence, the findings of this meta-analysis suggest that LAD bears little prognostic or therapeutic benefit in patients with uterine sarcoma. Systematic LAD may not be recommended in patients with uLMS or ESS unless the patient has obvious extrauterine involvement, clinically suspicious enlarged nodes, or advanced sarcomas.

  • Lymphadenectomy
  • Uterine sarcoma
  • Uterine leiomyosarcoma
  • Endometrial stromal sarcoma
  • Meta-analysis

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.